R Squared’s Regenxbio RGNX Stock Holding History

R Squared’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,310	Closed	-$17.9K	–	1227
2024 Q4	$17.9K	Buy	+2,310	New	+$21.7K	0.02%	933

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

R Squared's RGNX Position: Q1 2025 in Review

R Squared sold out of Regenxbio (RGNX) in Q1 2025, closing a stake of 2,310 shares — an estimated $17.9K sold.

R Squared first reported a position in RGNX in Q4 2024 and held it in 1 quarter. The position peaked at $17.9K in Q4 2024. 164 funds tracked by Wall St. Rank hold RGNX as of Q1 2025.

R Squared reported no remaining Regenxbio position as of Q1 2025 after selling out during the quarter.
R Squared sold 2,310 Regenxbio shares in Q1 2025, an estimated $17.9K.
R Squared first reported a position in Regenxbio in Q4 2024 and held it in 1 quarter.
R Squared's Regenxbio position peaked at $17.9K in Q4 2024.
164 funds tracked by Wall St. Rank held Regenxbio as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.